Published in Infect Immun on June 01, 2004
Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol (2008) 1.59
Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. Nat Immunol (2013) 1.46
Regulation of the autophagic bcl-2/beclin 1 interaction. Cells (2012) 0.98
Bacteremia causes hippocampal apoptosis in experimental pneumococcal meningitis. BMC Infect Dis (2010) 0.89
Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell (1993) 7.25
Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med (1999) 7.24
Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med (1993) 6.88
Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med (1997) 5.73
Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol (2001) 4.49
Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol (2000) 3.58
Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci U S A (1999) 3.35
Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol (1999) 2.92
BCL-2 gene family and the regulation of programmed cell death. Cancer Res (1999) 2.89
Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron (1994) 2.84
Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group. J Infect Dis (1990) 2.80
Targeted disruption of Bcl-2 alpha beta in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc Natl Acad Sci U S A (1994) 2.66
Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis. J Clin Invest (2002) 2.50
Adverse outcomes of bacterial meningitis in school-age survivors. Pediatrics (1995) 1.91
Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trends Neurosci (2002) 1.78
bcl-2 deficiency in mice leads to pleiotropic abnormalities: accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res (1995) 1.75
Apoptosis in sepsis: a new target for therapeutic exploration. FASEB J (2001) 1.73
Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat Med (1999) 1.71
Apoptosis of neurons in the dentate gyrus in humans suffering from bacterial meningitis. J Neuropathol Exp Neurol (1999) 1.38
Reactive oxygen intermediates contribute to necrotic and apoptotic neuronal injury in an infant rat model of bacterial meningitis due to group B streptococci. J Clin Invest (1996) 1.37
Overexpression of Bcl-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in vivo. J Neurosci (1996) 1.37
Anti-inflammatory treatment influences neuronal apoptotic cell death in the dentate gyrus in experimental pneumococcal meningitis. J Neuropathol Exp Neurol (1996) 1.36
Inactivation of bcl-2 results in progressive degeneration of motoneurons, sympathetic and sensory neurons during early postnatal development. Neuron (1996) 1.35
Neurotoxicity of pneumolysin, a major pneumococcal virulence factor, involves calcium influx and depends on activation of p38 mitogen-activated protein kinase. Neurobiol Dis (2002) 1.28
A mouse model of Streptococcus pneumoniae meningitis mimicking several features of human disease. Acta Neuropathol (2001) 1.21
Neuroprotective effect of excitatory amino acid antagonist kynurenic acid in experimental bacterial meningitis. J Infect Dis (1996) 1.16
Tumor necrosis factor-alpha contributes to apoptosis in hippocampal neurons during experimental group B streptococcal meningitis. J Infect Dis (1997) 1.06
Pneumococcal meningitis. Late neurologic sequelae and features of prognostic impact. Arch Neurol (1984) 1.06
Effect of deficiency of tumor necrosis factor alpha or both of its receptors on Streptococcus pneumoniae central nervous system infection and peritonitis. Infect Immun (2001) 1.05
Induction of necrosis and apoptosis of neutrophil granulocytes by Streptococcus pneumoniae. Clin Exp Immunol (2000) 1.04
Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice. Ann Neurol (2002) 1.04
Neurotoxicity of glia activated by gram-positive bacterial products depends on nitric oxide production. Infect Immun (1996) 0.97
Rifampin reduces production of reactive oxygen species of cerebrospinal fluid phagocytes and hippocampal neuronal apoptosis in experimental Streptococcus pneumoniae meningitis. J Infect Dis (2000) 0.95
Deciphering the apoptotic pathway: all roads lead to death. Immunol Cell Biol (1998) 0.93
Targeted disruption of the bcl-2 gene in mice exacerbates focal ischemic brain injury. Metab Brain Dis (1999) 0.92
The suppression of T cell apoptosis influences the severity of disease during the chronic phase but not the recovery from the acute phase of experimental autoimmune encephalomyelitis in mice. J Neuroimmunol (2002) 0.91
Age-related hippocampal changes in Bcl-2:Bax ratio, oxidative stress, redox-active iron and apoptosis associated with aluminum-induced neurodegeneration: increased susceptibility with aging. Neurotoxicology (1999) 0.91
Bilateral hippocampal volume loss in patients with a history of encephalitis or meningitis. Epilepsia (1996) 0.91
Spatial memory and learning deficits after experimental pneumococcal meningitis in mice. Neurosci Lett (2000) 0.90
Expression of death-related proteins in dentate granule cells in human bacterial meningitis. Brain Pathol (2001) 0.87
Caspases -2, -3, -6, and -9, but not caspase-1, are activated in sepsis-induced thymocyte apoptosis. Shock (2000) 0.86
Endotoxic shock leads to apoptosis in vivo and reduces Bcl-2. Shock (1996) 0.86
Oxidative stress in bacterial meningitis. Brain Pathol (1999) 0.86
Organotypic hippocampal cultures. A model of brain tissue damage in Streptococcus pneumoniae meningitis. J Neuroimmunol (2001) 0.84
A simple technique for evaluation of vitality loss in aging mice, by testing their muscular coordination and vigor. Exp Gerontol (1978) 0.84
Transcriptional regulation of caspases in experimental pneumococcal meningitis. Brain Pathol (2001) 0.79
Granulocytes in the subarachnoid space of humans and rabbits with bacterial meningitis undergo apoptosis and are eliminated by macrophages. Acta Neuropathol (1998) 0.79
bcl-2 prolongs neuronal survival during hypoxia-induced apoptosis. Brain Res Mol Brain Res (1999) 0.79
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet (2008) 3.68
Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity (2008) 3.67
Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol (2005) 3.42
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain (2011) 3.38
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med (2012) 2.90
New glucocorticoids on the horizon: repress, don't activate! J Rheumatol (2005) 2.70
Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev (2010) 2.66
Lyme disease--current state of knowledge. Dtsch Arztebl Int (2009) 2.53
Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood (2011) 2.44
Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry (2013) 2.23
Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet (2005) 2.20
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol (2004) 2.11
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology (2013) 2.02
An optical coherence tomography study on degeneration of retinal nerve fiber layer in rats with autoimmune optic neuritis. Invest Ophthalmol Vis Sci (2012) 2.02
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med (2002) 1.91
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med (2005) 1.79
Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology (2012) 1.78
Neurological deficits caused by tissue hypoxia in neuroinflammatory disease. Ann Neurol (2013) 1.70
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry (2012) 1.66
Circulating monocytes engraft in the brain, differentiate into microglia and contribute to the pathology following meningitis in mice. Brain (2006) 1.63
Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med (2009) 1.63
Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev (2002) 1.61
Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci U S A (2009) 1.56
Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions. Exp Neurol (2006) 1.55
PavA of Streptococcus pneumoniae modulates adherence, invasion, and meningeal inflammation. Infect Immun (2005) 1.54
Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol (2002) 1.53
Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol (2007) 1.52
Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain (2010) 1.52
Short-term rifampicin pretreatment reduces inflammation and neuronal cell death in a rabbit model of bacterial meningitis. Crit Care Med (2009) 1.51
Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9). FASEB J (2003) 1.48
Towards individualised multiple-sclerosis therapy. Lancet Neurol (2005) 1.46
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler (2012) 1.46
Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol (2004) 1.45
Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS One (2009) 1.44
Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain (2007) 1.42
Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. J Neurol Neurosurg Psychiatry (2012) 1.41
A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol (2012) 1.34
Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler (2011) 1.33
Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol (2013) 1.30
Neurotoxicity of pneumolysin, a major pneumococcal virulence factor, involves calcium influx and depends on activation of p38 mitogen-activated protein kinase. Neurobiol Dis (2002) 1.28
Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit Rev Immunol (2009) 1.27
Impairment of mitochondrial calcium handling in a mtSOD1 cell culture model of motoneuron disease. BMC Neurosci (2009) 1.26
Intra- and internerve cross-sectional area variability: new ultrasound measures. Muscle Nerve (2012) 1.25
Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone. Antimicrob Agents Chemother (2003) 1.25
Decreased virulence of a pneumolysin-deficient strain of Streptococcus pneumoniae in murine meningitis. Infect Immun (2002) 1.23
Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol (2008) 1.22
Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol (2005) 1.20
Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol Dis (2008) 1.20
Cholesterol-dependent actin remodeling via RhoA and Rac1 activation by the Streptococcus pneumoniae toxin pneumolysin. Proc Natl Acad Sci U S A (2007) 1.19
Toll-like receptor stimulation enhances phagocytosis and intracellular killing of nonencapsulated and encapsulated Streptococcus pneumoniae by murine microglia. Infect Immun (2009) 1.18
Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain (2006) 1.17
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol (2013) 1.17
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol (2011) 1.17
Dose-dependent activation of microglial cells by Toll-like receptor agonists alone and in combination. J Neuroimmunol (2004) 1.16
Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. Mult Scler (2013) 1.16
Amyloid beta peptide 1-40 enhances the action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures. J Neurochem (2005) 1.14
PavB is a surface-exposed adhesin of Streptococcus pneumoniae contributing to nasopharyngeal colonization and airways infections. Mol Microbiol (2010) 1.14
Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. J Mol Med (Berl) (2010) 1.13
Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis. J Neurol (2011) 1.12
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
Mechanisms of injury in bacterial meningitis. Curr Opin Neurol (2010) 1.11
Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain (2003) 1.11
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol (2012) 1.11
Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One (2011) 1.10
Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve (2004) 1.09
Naive CD8 T-cells initiate spontaneous autoimmunity to a sequestered model antigen of the central nervous system. Brain (2008) 1.08
Toll-like receptor activation reveals developmental reorganization and unmasks responder subsets of microglia. Glia (2012) 1.08
Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. Ann Neurol (2012) 1.07
Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study. Am J Pathol (2006) 1.06
Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol (2007) 1.05
Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler (2011) 1.05
Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Ther Adv Neurol Disord (2011) 1.05
Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol Dis (2007) 1.05
Toll-like receptor prestimulation increases phagocytosis of Escherichia coli DH5alpha and Escherichia coli K1 strains by murine microglial cells. Infect Immun (2008) 1.04
α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J Neural Transm (Vienna) (2012) 1.04
Therapies for multiple sclerosis: translational achievements and outstanding needs. Trends Mol Med (2013) 1.04
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler (2011) 1.03
Preclinical retinal neurodegeneration in a model of multiple sclerosis. J Neurosci (2012) 1.03
Analysis of maturation states of rat bone marrow-derived dendritic cells using an improved culture technique. Histochem Cell Biol (2002) 1.02
MRI of optic neuritis in a rat model. Neuroimage (2008) 1.02
Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann Neurol (2011) 1.02
Astrocytes are less efficient in the removal of apoptotic lymphocytes than microglia cells: implications for the role of glial cells in the inflamed central nervous system. J Neuropathol Exp Neurol (2002) 1.02
Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int J Mol Sci (2012) 1.02
Progressive multifocal leukoencephalopathy and natalizumab. J Neurol (2011) 1.01
Varicella zoster virus cerebellitis in a 66-year-old patient without herpes zoster. Lancet (2006) 1.01
Minimizing the release of proinflammatory and toxic bacterial products within the host: a promising approach to improve outcome in life-threatening infections. FEMS Immunol Med Microbiol (2005) 1.01